Biacore™ 4000 by GE Healthcare

Manufacturer GE Healthcare
  |  2 reviews

Biacore™ 4000 by GE Healthcare product image
Biacore™ 4000
Request Pricing

Receive your quote directly from the manufacturer.

Average Rating: 3.9
2 Scientists have reviewed this product

4 out of 5
Ease of use
4 out of 5
After sales service
4 out of 5
Value for money

Rating: 3.0

"The Biacore 4000 allows a range of types of binding interactions to be explored, from screening of fragment libraries against multiple targets in parallel to kinetic characterisation of hits and profiling hit compounds in hit to lead campaigns. The instrument is sensitive and efficient for these applications, it produces high quality data but the data analysis software provided with the instrument is not always appropriate for formatting data sets for presentations and for tracking in company databases. It is necessary to provide separate analyses for these capabilities, adding to the overall costs of utilizing this technology."

Review date: 03 Oct 2012 | Biacore™ 4000
  • Status:


  • Member since: 2011

  • Organization: Astrazeneca

  • Ease of use
    4 out of 5
    After sales service
    5 out of 5
    Value for money
    5 out of 5
Rating: 4.7

  • Application Area:Biophysics

"The Biacore 4000 has greatly inceased the sample testing throughput available to our lab. This has enabled us to complete fragment screening campaigns and concentration response follow up both efficiently and in a timely manner. The data quality and particularly the signal-to-noise ratio is exceptionally good for the data we have generated, enabling us to more easily distinguish and characterise the best compound hits for progression."

Review date: 06 Sep 2012 | Biacore™ 4000
Biacore 4000 offers a powerful solution for large-scale label-free interaction analysis, delivering high quality data without compromising on throughput.

The system hardware and software provide innovative solutions for maximizing productivity in key areas such as antibody screening & selection, and small molecule drug discovery.

Two extension software packages provide tailored tools for antibody screening and characterization, and screening of fragments and LMW compounds, respectively, allowing customers to fully exploit the capacity of Biacore 4000 for these applications.


  • Sensitivity and high-quality binding data for confident selection of candidates based on biologically relevant binding properties (selectivity, affinity and kinetics)
  • Rapid analysis direct from crude samples (e.g. hybridoma supernatants, cell lysates)
  • 60 hours unattended operation with parallel analysis of up to 4800 interactions in 24 h
  • Evaluation of up to 4800 interactions in less than 2 hrs resolves data evaluation bottlenecks
  • Validated software facilitates 21 CFR Part 11 compliance